Effects of Xuezhikang on low-density lipoprotein subfractions and oxidized LDL in patients with hyperlipidemia
Author:
Affiliation:

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease & Fu Wai Hospital & National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China)

Clc Number:

R5

  • Article
  • | |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Aim To investigate the effects of Xuezhikang (XZK) on low-density lipoprotein (LDL) subfractions and oxidized low-density lipoprotein (ox-LDL) in patients with hyperlipidemia. Methods A total of 40 subjects (20 patients with hyperlipidemia and 20 healthy subjects) who were not treated with lipid-lowering drugs were selected consecutively and divided into the XZK group (n=20) and the control group (n=20). The plasma LDL subfractions, ox-LDL were examined by using the Lipoprint system at baseline and again after 8 weeks. Results Data showed that XZK could significantly decrease not only plasma LDLC levels, total cholesterol, triglycerides, and apolipoprotein B (P<0.05), but also ox-LDL (P<0.05). At the same time, XZK reduced the concentration of small LDLC (P<0.05) and the percentage of the small LDL subfraction (P<0.05). Conclusion XZK treatment for 8 weeks significantly improved the blood lipid profile, reduced the concentration and percentage of atherogenic small LDLC, and reduced the level of oxidative stress.

    Reference
    Related
    Cited by
Get Citation

ZHANG Yue, XU Ruixia, ZHANG Yan, WU Yaru, LI Jianjun. Effects of Xuezhikang on low-density lipoprotein subfractions and oxidized LDL in patients with hyperlipidemia[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(3):229-232.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 03,2019
  • Revised:August 09,2019
  • Online: January 20,2020
Article QR Code